European approval for Taxotere (docetaxel) in prostate cancer

Nov 4 2004

Aventis, part of the sanofi-aventis Group announced today that the European Commission has approved Taxotere (docetaxel) Injection Concentrate for use in combination with prednisone as a treatment for men with androgen-independent (hormone- refractory) metastatic prostate cancer.

The Commission approval is based on the results of a large landmark phase III clinical trial, TAX 327, which demonstrated that a Taxotere-based regimen significantly reduced the risk of death by 24 percent in men with androgen- independent (hormone-refractory) metastatic prostate cancer. Investigators in the TAX 327 trial also reported that Taxotere significantly improved patients' Prostate Specific Antigen (PSA) response by 43 percent and improved pain response by 59 percent, relative to mitoxantrone.

In the TAX 327 trial, investigators reported that Taxotere was well tolerated. The most commonly observed adverse events in TAX 327 were alopecia, fatigue and nausea. Grade 3-4 neutropenia was reported more frequently in the Taxotere group than the mitoxantrone group (32 percent vs 21.7 percent, p=0.004).

The results of this pivotal study were presented in June 2004 at the American Society of Clinical Oncology meeting (ASCO). On May 19, 2004, the U.S. Food and Drug Administration granted Taxotere approval for use in combination with prednisone as a treatment for men with hormone-refractory metastatic prostate cancer.

Prostate cancer ranks third worldwide in cancer incidence and sixth in cancer mortality among men. In the United States, more than 230,000 American men will be diagnosed with prostate cancer this year, and 30,000 will die of the disease. In the European Union, 138,000 new cases will be diagnosed, and 45,000 patients will die of the disease.

Current therapy for advanced prostate cancer is hormonal manipulation (i.e., blockage of androgen hormones like testosterone that would otherwise stimulate the growth of prostate cancer cells). However, the effects of this treatment typically last between 24 and 36 months, at which time patients may become refractory to hormonal therapy and be considered candidates for chemotherapy, such as Taxotere.

http://www.sanofi-aventis.com/